Dr. James Stevenson
University of Notre Dame, Notre Dame, IN - 1988
Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA - 1992
Thomas Jefferson University Hospital, Philadelphia, PA - 1995
Thomas Jefferson University Hospital, Philadelphia, PA - 1998
Dr. James Stevenson is a medical oncologist and hematologist at the Cleveland Clinic located in Cleveland, Ohio. Dr. Stevenson joined the staff at the Cleveland Clinic in 2012 and in July of 2015 he was appointed vice chairman of the department of hematology and medical oncology.
Dr. Stevenson earned his undergraduate degree in 1988 at the University of Notre Dame located in Notre Dame, Indiana before going on to earn his medical degree from Jefferson Medical College of Thomas Jefferson University located in Philadelphia, Pennsylvania in 1992. Dr. Stevenson went on to complete his internship in internal medicine at the University of Florida College of Medicine - Shands Medical Center in Gainesville, Florida and subsequently pursued both his residency (internal medicine) and fellowship (hematology) at Thomas Jefferson University Hospital in Philadelphia which he completed in 1995 and 1998, respectively.
Clinical and Laboratory Research
Board-certified in internal medicine and medical oncology, Dr. Stevenson’s clinical expertise and research focus are on the management of malignancies relative to the lungs, including mesothelioma.
Dr. Stevenson is part of a team of experts at the Cleveland Clinic’s Taussig Cancer Institute that employs a multidisciplinary approach to the care of patients with lung cancer and mesothelioma. He is responsible for organizing the Multidisciplinary Pleural Mesothelioma Center at the Taussig Cancer Institute where medical and radiation oncologists, pulmonologists, thoracic surgeons, pathologists, and palliative care experts deliver quality care to patients and offer innovative treatments based on the latest research. The goal of the center is to streamline and shorten the time to diagnosis for its patients. Dr. Stevenson’s degree of expertise in his field, as well as his compassion for his patients, is reflected in online reviews by his patients who have said “I would not be alive without Dr. Stevenson and the level of care and concern he has given me” and “…Dr. Stevenson helped save my life and I could not be happier about that.”
Dr. Stevenson’s most recent publications relative to mesothelioma treatment and research include the following:
Ai J, Stevenson JP. Current issues in malignant pleural mesothelioma evaluation and management. Oncologist. 2014 Sep;19(9):975-84. Epub 2014 Jul 24.
Stevenson JP, Kindler HL, Papasavvas E, Sun J, Jacobs-Small M, Hull J, Schwed D, Ranganathan A, Newick K, Heitjan DF, Langer CJ, McPherson JM, Montaner LJ, Albelda SM. Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients. Oncoimmunology. 2013 Aug 1;2(8):e26218. Epub 2013 Aug 27.
Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, Jänne PA, Quinn DI, Koczywas MN, Brahmer JR, Albain KS, Taber DA, Armato SG 3rd, Vogelzang NJ, Chen HX, Stadler WM, Vokes EE. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol. 2012 Jul 10;30(20):2509-15. Epub 2012 Jun 4.Sources